J
John G.F. Cleland
Researcher at National Institutes of Health
Publications - 1276
Citations - 125527
John G.F. Cleland is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Heart failure & Ejection fraction. The author has an hindex of 137, co-authored 1172 publications receiving 110227 citations. Previous affiliations of John G.F. Cleland include Northwestern University & Imperial College London.
Papers
More filters
Journal ArticleDOI
Non-invasive evaluation of cardiac function in young patients with type 1 diabetes.
TL;DR: The chamber size, wall thickness, and systolic function of the left ventricle are normal in most young Type 1 diabetic patients who have few microvascular complications.
Journal ArticleDOI
Ruling out heart failure in primary-care: the cost-benefit of pre-screening using NT-proBNP and QRS width.
TL;DR: Use of NT-proBNP by PCPs to detect major-LVSD and major-SHD in patients with suspected HF could reduce referrals for specialist HF-assessment, provide cost-avoidance compared to direct referral and improve the efficiency of care.
Journal ArticleDOI
Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study.
John G.F. Cleland,Paul W. Armstrong,John D. Horowitz,B.M. Massie,M. Packer,P.A. Poole-Wilson,L. Rydén +6 more
TL;DR: The beneficial effect of ACE inhibitors on mortality has been established in a series of trials, but in clinical practice, ACE inhibitors are commonly administered in doses much lower than those shown to be effective in the landmark trials.
Journal ArticleDOI
Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?
Faiez Zannad,Wendy Gattis Stough,Stuart J. Pocock,Peter Sleight,William C. Cushman,John G.F. Cleland,John J.V. McMurray,Eva Lonn,Nancy L. Geller,Hans Wedel,Eric Abadie,Angeles Alonso-Garcia,Bertram Pitt +12 more
TL;DR: Cooperative efforts among physicians, clinical trialists, regulators, and sponsors are needed to address unresolved issues including re-defining therapeutic targets that are meaningful to patients with diabetes, determining the appropriate length of follow-up for future trials, and considering the ethical and operational challenges of non-inferiority designs.
Journal ArticleDOI
Neuroendocrine activation after myocardial infarction: causes and consequences
TL;DR: In patients suffering from myocardial infarction, NeuropeptideY concentrations peak approximately eight hours after myocardious infarctions and return to thenormal range within two to three days unless heart failure supervenes, in which case theymay become chronically elevated in patientssuffering from heart failure.